Image credit: https://www.hamamatsu-news.de/promo/laser/
On May 12th, Hamamatsu announced its financial results for Q1 2021. Due to the companies reporting cycle, this is its second fiscal quarter. Overall group quarterly sales reached ¥42.9bn, compared with ¥38.5bn in Q1 2020, an increase of approximately +11.5% year-on-year. The segment reporting provides some insight into the sales performance of its portfolio of solutions specifically for medical imaging applications.
The Opto-semiconductor Medical-bio Segment
The Hamamatsu business is segmented into three reportable segments; ‘Electron Tubes’, ‘Opto semiconductor’ and ‘Imaging and Measurement Instruments’. These business units are further segmented by industry and application. The “Opto-semiconductor Medical Bio” segment encompasses silicon photodiodes for medical applications, line and area image sensors and flat-panel detectors. The Q1 2021 financial report indicates that quarterly sales returned to growth following three consecutive quarters of sales decline. Quarterly sales from the Opto-semiconductor medical-bio segment reached ¥10.5bn, compared with ¥9.1bn in Q1 2020, an increase of approximately +15% year-on-year. The sales growth during the quarter was driven by higher demand for silicon photodiodes for computed tomography (CT), partially offset by lower sales of flat-panel sensors used for dental applications, although the company reported that sales were recovering from the lower demand triggered by the Coronavirus pandemic. The company noted that sales for Si photodiodes for CT applications was strong in both Japan as well as overseas.